Newsfeeds - Spark Newswire

1 minute read

Biogen Launches High-Dose Spinraza Trial In Evrysdi Treated Patients: What You Need To Know

Today, 9:58 AM

Biogen Inc’s (NASDAQ:BIIB) Spinraza (nusinersen), spinal muscular atrophy (SMA) drug launched in early 2017, faces new competition from Roche Holdings…

BIIB

3 minute read

Biogen Plans To Initiate Phase 3b Study Evaluating Potential Benefit Of A Higher Dose Of Nusinersen In Patients Previously Treated With Evrysdi

By Benzinga Newsdesk

Today, 9:58 AM

Biogen Inc. (NASDAQ:BIIB) today announced plans to initiate a global Phase 3b clinical study, ASCEND. The ASCEND study is designed to evaluate the clinical outcomes and assess the safety of a higher dose of

BIIB

4 minute read

The Week Ahead In Biotech (Sept. 12-18): Calliditas FDA Decision, Adcom Review For Pfizer/BioNTech COVID-19 Vaccine, Oncology Conference And IPOs

By Shanthi Rexaline

Today, 9:58 AM

Biotech stocks retreated in the holiday-shortened week ending Sept. 10, reversing course from the previous week.

ALRN

1 minute read

News

‘Biogen trials for Alzheimer’s drug excluded much of the targeted patient pool, study finds’ -STAT

By Michael Horton

Today, 9:58 AM

https://www.statnews.com/pharmalot/2021/09/10/biogen-alzheimer-fda-medicare/

BIIB

1 minute read

News

Why Biogen Shares Are Falling

By Henry Khederian

Today, 9:58 AM

Biogen Inc (NASDAQ: BIIB) shares are trading lower by 7% at $298.83 following reports the company's CEO highlighted a slower-than-anticipated launch of Aduhelm.

BIIB

1 minute read

FDA
News

‘#BIIB execs are speaking at an investor conference right now, remarking in more public detail than ever before the issues that are negatively impacting the commercial launch of Aduhelm.’ -STAT News Reporter Tweet

By Benzinga Newsdesk

Today, 9:58 AM

https://twitter.com/adamfeuerstein/status/1435962066037264385

BIIB

1 minute read

Congress Asks For Approval Documents Of Biogen’s Alzheimer’s Drug: Report

By Vandana Singh

Today, 9:58 AM

Lawmakers have requested data and documents from the FDA related to the agency's controversial approval of Biogen Inc's (NASDAQ: BIIB) Alzheimer's drug Aduhelm.

BIIB

1 minute read

News

Lawmakers Cite ‘Apparent Anomalies’ In Aduhelm Approval Process

By Michael Horton

Today, 9:58 AM

-Bloomberg

BIIB

5 minute read

Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates

By Shanthi Rexaline

Today, 9:58 AM

August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining.

ABBV

1 minute read

Analyst Ratings

Expert Ratings For Biogen

By Benzinga Insights

Today, 9:58 AM

Analysts have provided the following ratings for Biogen (NASDAQ:BIIB) within the last quarter:

BIIB